Is retatrutide just a stronger version of tirzepatide?

Retatrutide activates GIP, GLP-1, and glucagon receptors; tirzepatide activates GIP and GLP-1 receptors. Adding glucagon-receptor activity changes the pharmacology, not just the strength of the same drug. The balance of those activities matters, so counting receptor targets is not a clinical ranking system.[1]

Retatrutide produced substantial weight reductions in its 48-week phase 2 obesity trial. Gastrointestinal adverse effects were common, and increases in heart rate were observed. Those findings show both efficacy and tradeoffs, rather than establishing that every person who tolerates tirzepatide will have a better experience with retatrutide.[1]

Separate trial averages should not be treated as a personalized head-to-head prediction. Comparisons need matched populations and attention to adverse events, discontinuation, and body composition. Trial-grade retatrutide is also not evidence that a product sold online under that name has the same identity or quality; the FDA has specifically warned about unapproved products marketed for weight loss.[1][2]